GAL-101 salt

DRUG2 trials

Sponsors

Galimedix Therapeutics Inc., Galimedix Therapeutics Inc

Conditions

Mild to Moderate Alzheimer's DiseaseNon-foveal geographic atrophy secondary to non-neovascular age-related macular degeneration

Phase 2

A phase 2, double-masked, randomized, multicenter, parallel group, placebo-controlled study to investigate the efficacy and safety of GAL-101, 2%, ophthalmic solution in patients with non-foveal geographic atrophy secondary to non-neovascular age-related macular degeneration: eDREAM study

RecruitingCTIS2024-519128-26-00

Galimedix Therapeutics Inc.Non-foveal geographic atrophy secondary to non-neovascular age-related macular degeneration

Start: 2025-05-22Target: 65Updated: 2025-10-22

A 28-Day Study of GAL-101 in Participants With Mild to Moderate Alzheimer's Disease

Not yet recruitingNCT07789873

Galimedix Therapeutics IncMild to Moderate Alzheimer's Disease

Start: 2027-02-28End: 2028-07-31Target: 100Updated: 2026-08-27